These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22818111)

  • 1. Growing prevalence of Providencia stuartii associated with the increased usage of colistin at a tertiary health care center.
    Hayakawa K; Marchaim D; Divine GW; Pogue JM; Kumar S; Lephart P; Risko K; Sobel JD; Kaye KS
    Int J Infect Dis; 2012 Sep; 16(9):e646-8. PubMed ID: 22818111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory investigation of a suspected outbreak caused by Providencia stuartii with intermediate resistance to imipenem at a long-term care facility.
    Mao YC; Chang CL; Huang YC; Su LH; Lee CT
    J Microbiol Immunol Infect; 2018 Apr; 51(2):214-219. PubMed ID: 27553450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.
    Mutlu Yilmaz E; Sunbul M; Aksoy A; Yilmaz H; Guney AK; Guvenc T
    Int J Antimicrob Agents; 2012 Oct; 40(4):332-6. PubMed ID: 22831842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.
    Docobo-Pérez F; Nordmann P; Domínguez-Herrera J; López-Rojas R; Smani Y; Poirel L; Pachón J
    Int J Antimicrob Agents; 2012 Mar; 39(3):251-4. PubMed ID: 22154856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital.
    Tumbarello M; Citton R; Spanu T; Sanguinetti M; Romano L; Fadda G; Cauda R
    J Antimicrob Chemother; 2004 Feb; 53(2):277-82. PubMed ID: 14688041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonality of Providencia stuartii isolates involved in outbreak that occurred in a burn unit.
    Saida NB; Thabet L; Messadi A; Bouselmi K; Turki A; Boukadida J
    Burns; 2008 Sep; 34(6):829-34. PubMed ID: 18241997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
    Giamarellou H
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii.
    Dizbay M; Tozlu DK; Cirak MY; Isik Y; Ozdemir K; Arman D
    J Antibiot (Tokyo); 2010 Feb; 63(2):51-3. PubMed ID: 19942947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection due to colistin-resistant Enterobacteriacae in critically-ill patients.
    Garbati MA; Bin Abdulhak A; Baba K; Sakkijha H
    J Infect Dev Ctries; 2013 Oct; 7(10):713-9. PubMed ID: 24129623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
    Cheng CY; Sheng WH; Wang JT; Chen YC; Chang SC
    Int J Antimicrob Agents; 2010 Mar; 35(3):297-300. PubMed ID: 20045293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-resistant Providencia stuartii expressing extended-spectrum beta-lactamase PER-1, originating in Kosovo.
    Poirel L; Bruderer T; Frei R; Bernabeu S; Graber P; Nordmann P
    J Antimicrob Chemother; 2008 Jun; 61(6):1392-3. PubMed ID: 18334492
    [No Abstract]   [Full Text] [Related]  

  • 12. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-expression of plasmid-mediated quinolone resistance-qnrA1 and blaVEB-1 gene in a Providencia stuartii strain.
    Nazik H; Bektöre B; Öngen B; Özyurt M; Baylan O; Haznedaroğlu T
    New Microbiol; 2011 Apr; 34(2):225-8. PubMed ID: 21617836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Providencia stuartii infection in a dog with severe skin ulceration and cellulitis.
    Papadogiannakis E; Perimeni D; Velonakis E; Kontos V; Vatopoulos A
    J Small Anim Pract; 2007 Jun; 48(6):343-5. PubMed ID: 17547643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections.
    Falagas ME; Rafailidis PI; Kasiakou SK; Hatzopoulou P; Michalopoulos A
    Clin Microbiol Infect; 2006 Dec; 12(12):1227-30. PubMed ID: 17121631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system.
    Pogue JM; Lee J; Marchaim D; Yee V; Zhao JJ; Chopra T; Lephart P; Kaye KS
    Clin Infect Dis; 2011 Nov; 53(9):879-84. PubMed ID: 21900484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Difficult-to-treat Gram-negative bone and joint infections: efficacy and safety of prolonged intravenous colistin.
    Valour F; Dutronc H; Dinh A; Cazorla C; Pavèse P; Lesens O; Uçkay I; Chidiac C; Ferry T;
    Int J Antimicrob Agents; 2013 Feb; 41(2):197-9. PubMed ID: 23146203
    [No Abstract]   [Full Text] [Related]  

  • 18. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction.
    Turkoglu M; Dizbay M; Ciftçi A; Aksakal FN; Aygencel G
    Int J Antimicrob Agents; 2012 Feb; 39(2):142-5. PubMed ID: 22115538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous and inhalational colistin-induced respiratory failure.
    Wahby K; Chopra T; Chandrasekar P
    Clin Infect Dis; 2010 Mar; 50(6):e38-40. PubMed ID: 20146630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and drug resistance characteristics of
    Liu J; Wang R; Fang M
    J Int Med Res; 2020 Oct; 48(10):300060520962296. PubMed ID: 33081537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.